spacer
home > ebr > summer 2003 > endurance: european biotech - surviving the storm
PUBLICATIONS
European Biopharmaceutical Review

Endurance: European Biotech - Surviving the Storm

'With the stock market upheaval ravaging the biotech industry, many opportunities have gone unexplored, many promising approaches have had no chance to prove themselves, and many good ideas have been left untested. At the same time, the assessment of biotech's potential has become more sober and pragmatic. The biotech industry is also more mature and is increasingly becoming part of the health care business mainstream. Better attuned to the realities, we can now more confidently pursue innovation in the service of better health care.'

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Reviewed by Dr Helen Abbott, Senior Consultant at Technomark Consulting Services Ltd and Editor of European Biopharmaceutical Review
spacer
Dr Helen Abbott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avacta and Cytiva collaborating on COVID-19 rapid test

Cambridge and Wetherby, UK, 08 April 2020: Avacta Group plc (AIM: AVCT), the developer of AffimerŽ biotherapeutics and reagents, is pleased to announce that it has entered into a collaboration with Cytiva, formerly known as GE Healthcare Life Sciences. The companies will develop and manufacture an Affimer-based point-of-care rapid test intended for screening of large populations to diagnose the COVID-19 coronavirus infection.
More info >>

White Papers

The Role of the CRO in Effective Risk-Based Monitoring

Medpace

The clinical trial industry is evolving. In an effort to improve participant safety and data integrity, regulators are encouraging trial sponsors to transition from a focused on-site monitoring approach they have traditionally employed toward a risk-based approach that utilizes a combination of centralized and on-site monitoring techniques to ensure patient safety and data quality. The Risk-Based Monitoring (RBM) paradigm has many potential advantages over established monitoring practices including enhanced patient safety and data integrity, more efficient and effective protocol design, reduced costs, and the ability to strategically adjust oversight in keeping with changes in risk level.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement